Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144

The TANGO study (ClinicalTrials.gov, NCT03446573) demonstrated that switching to dolutegravir/lamivudine (DTG/3TC) was non-inferior to continuing tenofovir alafenamide-based regimens (TBR) through week 144. Retrospective baseline proviral DNA genotypes were performed for 734 participants (post-hoc a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ruolan, Wright, Jonathan, Saggu, Parminder, Ait-Khaled, Mounir, Moodley, Riya, Parry, Chris M., Lutz, Thomas, Podzamczer, Daniel, Moore, Richard, Górgolas Hernández-Mora, Miguel, Kinder, Clifford, Wynne, Brian, van Wyk, Jean, Underwood, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300912/
https://www.ncbi.nlm.nih.gov/pubmed/37376649
http://dx.doi.org/10.3390/v15061350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300912/
https://www.ncbi.nlm.nih.gov/pubmed/37376649
http://dx.doi.org/10.3390/v15061350

Ejemplares similares